Visit us at Poster #1021 on Monday, February 8th.
Meeting Summary: The combination of next-generation sequencing and analysis as applied to experiments studying the cancer genome has revolutionized our understanding of cancer biology. Large-scale cancer genomics has further established a baseline that is now poised to effect the translation of cancer genomics into the clinical setting, effectively transforming patient care. The barriers and challenges to translation are significant, not the least of which involves the transition of research-grade computational and interpretational analysis to clinical-grade analysis. Assays must be highly refined, validated and accurate. How the use of genomic approaches to monitor patient response to therapy, the onset of acquired resistance to therapy and other aspects of patient care will be accepted as a more sensitive partner with conventional imaging approaches must be addressed. Appropriate assignment of therapies to specific gene/protein alterations also will be of paramount importance, especially as the numbers and types of targeted therapies increase. Genomics will also impact our understanding of the immune system's interaction with tumors, leading to the development of personalized vaccine strategies that may provide more durable responses. Specific goals of the meeting include: 1) Providing an overview of computational tools, any gaps in variant detection capabilities and their challenges for clinical implementation; 2) Discussing specific approaches to identify gene-therapy combinations, specifically addressing the difficulty of assessing the impact of DNA mutations on protein function; 3) Identification of the significant efforts ongoing in blood-based ("liquid") biopsy of patients on therapy or following resection surgery; 4) Presentation of current efforts to utilize genomics of individual tumors to inform immunotherapy development; 5) Discussion of efforts at data integration, across "omic" platforms, and also the integration of genomic data with more conventional pathology-based evidence/data. The anticipated outcomes will be the exchange of ideas among international participants on how genomics will impact cancer care and clinical practice and what gaps exist in their existing approaches, as well as development of new collaborations and new enthusiasm for helping to build on the potential of genome-guided approaches to cancer medicine.